Sanofi (SAN) News Today €98.70 +1.59 (+1.64%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlinesSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period SandboxAQ Selected by Sanofi for Quantitative AI-Driven Biomarker IdentificationOctober 30 at 9:49 AM | tmcnet.comSanofi (EPA:SAN) Stock Passes Above 200 Day Moving Average - Here's WhyOctober 30 at 2:49 AM | americanbankingnews.comSanofi Launches Beyfortus Immunization Against RSV For Infants In Canada This FallOctober 28, 2024 | markets.businessinsider.comSanofi Positioned for Growth: Analyst David Risinger Recommends Buy Amid Strong Earnings OutlookOctober 28, 2024 | markets.businessinsider.comAnalysts Are Neutral on Top Healthcare Stocks: Sanofi (SNYNF), Siegfried Holding AG (SGFEF)October 27, 2024 | markets.businessinsider.comSanofi Profit, Sales Beat EstimatesOctober 25, 2024 | msn.comSanofi Profit Growth Beats Market View on Early Start of Vaccine SalesOctober 25, 2024 | money.usnews.comSanofi Expected to Report Higher Sales; Capital Allocation in Focus -- Earnings PreviewOctober 24, 2024 | marketwatch.comHow Sanofi Was Caught in The Middle of a €16 Billion Public BrawlOctober 24, 2024 | finance.yahoo.comCD&R Faces Tough Road to 20% Returns With SanofiOctober 23, 2024 | bloomberg.comSanofi Deal Jitters Imperil Stock’s Big ReboundOctober 22, 2024 | msn.comSanofi deal offers only partial headache reliefOctober 21, 2024 | ft.comSanofi confirms €16 billion sale of painkiller Doliprane to US investorsOctober 21, 2024 | yahoo.comSanofi’s $17bn sale of Opella to US investors advances following government dealOctober 21, 2024 | finance.yahoo.comFrench state takes stake in Sanofi unit to smooth €15.5bn US dealOctober 21, 2024 | ft.comPress Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcareOctober 21, 2024 | uk.finance.yahoo.comPress Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcareOctober 21, 2024 | uk.finance.yahoo.comCD&R Nears Sanofi OTC Deal After Signing With GovernmentOctober 21, 2024 | bloomberg.comCD&R Nears Sanofi OTC Deal After Signing With GovernmentOctober 21, 2024 | bloomberg.comSanofi reaches deal on terms of sale of consumer health arm, say French government sourcesOctober 21, 2024 | msn.comSanofi reaches deal on terms of sale of consumer health arm, say French government sourcesOctober 21, 2024 | msn.comPAI Partners raises bid for Sanofi's Opella, source saysOctober 19, 2024 | msn.comSanofi 'surprised' by PAI Partners' raised bid for Opella unitOctober 19, 2024 | msn.comSanofi Set to Sign Consumer Health Deal With CD&R This WeekendOctober 19, 2024 | bloomberg.comUBS Remains a Buy on Sanofi (SNYNF)October 17, 2024 | markets.businessinsider.comExscientia advances two additional discovery programs with SanofiOctober 17, 2024 | finance.yahoo.comSanofi and Orano Join Forces to Develop Next-generation Radioligand MedicinesOctober 17, 2024 | uk.finance.yahoo.comExscientia Achieves Milestones for Two Programmes in Sanofi CollaborationOctober 16, 2024 | finance.yahoo.comSanofi in Talks With French Government to Address Concerns on Opella DealOctober 16, 2024 | msn.comFrench Sanofi workers to strike in bid to block consumer health unit deal, union official saysOctober 16, 2024 | msn.comSanofi workers in France to strike over sale of consumer health unit, union official saysOctober 16, 2024 | msn.comSanofi: Information concerning the total number of voting rights and shares - September 2024October 16, 2024 | uk.finance.yahoo.comFrance warns it could block €15.5bn Sanofi consumer health dealOctober 15, 2024 | ft.comUS Private Equity’s Sanofi Deal Breaches the French WallOctober 15, 2024 | bloomberg.comFrance seeks job guarantees from Sanofi over Doliprane painkiller productionOctober 14, 2024 | msn.comSanofi Stirs Healthy Rivalries for Lazard and CenterviewOctober 14, 2024 | bloomberg.comCD&R Plans Measures to Ease French Worries on Sanofi DealOctober 14, 2024 | bloomberg.comFrance to Formally Screen CD&R Purchase of Sanofi Unit: FigaroOctober 14, 2024 | msn.comFrance Weighs State Stake in Sanofi Unit Being Sold to CD&ROctober 14, 2024 | bloomberg.comSanofi in talks to sell stake in consumer healthcare unit to CD&ROctober 14, 2024 | finance.yahoo.comSanofi in talks to sell consumer healthcare business that makes DulcolaxOctober 12, 2024 | marketwatch.comCD&R Nears €15 billion Deal for Sanofi Consumer Health UnitOctober 11, 2024 | bloomberg.comSanofi Enters Talks to Sell Controlling Stake in Consumer Health Unit to CD&ROctober 11, 2024 | msn.comSanofi and Regeneron introduces medication for COPDOctober 9, 2024 | msn.comSanofi’s rare disease drug finds yet another homeOctober 4, 2024 | finance.yahoo.comSanofi Healthcare Bidders Revising Offers Over Talc ConcernsOctober 4, 2024 | bloomberg.comRecordati to Buy Global Rights to Sanofi's Enjaymo for $825 MillionOctober 4, 2024 | morningstar.comRecordati buys rights to rare immune disorder drug from Sanofi for $825 millionOctober 4, 2024 | msn.comSanofi blockbuster drug wins clearance in US for lung diseaseSeptember 27, 2024 | detroitnews.comSanofi: Availability of the Q3 2024 Aide mémoireSeptember 26, 2024 | finanznachrichten.de Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SAN and its competitors with MarketBeat's FREE daily newsletter. Email Address I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. SAN Media Mentions By Week SAN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAN News Sentiment▼0.440.41▲Average Medical News Sentiment SAN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAN Articles This Week▼56▲SAN Articles Average Week Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SAN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Deutsche Bank Aktiengesellschaft News Today Bayer Aktiengesellschaft News Today Fielmann Group News Today Fresenius SE & Co. KGaA News Today Genfit News Today Sartorius Stedim Biotech News Today Siemens Healthineers News Today Merck KGaA News Today Fresenius Medical Care News Today Carl Zeiss Meditec News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (EPA:SAN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
